News Articles

On September 20, 2024 BVT announced that Mr. Kyle Appleby has resigned as the Company’s Chief Financial Officer and Corporate Secretary, effective September 12, 2024.

Read More

On August 19, 2024 BVT announced the Company’s proprietary Vectorite with Clonostachys Rosea CR-7 (CR-7) has been approved by Mexico’s COFEPRIS (The Federal Commission for Protection from Sanitary Risks), the …

Read More

On July 24, 2024 BVT announced progress into markets in North Africa and the Middle East through strategic partnerships with leading, locally-connected agribusinesses in four key countries to commercialize the …

Read More

On July 10, 2024 BVT announced that it has closed the previously announced  debt settlement agreements (the “Settlement Agreements”) to fully settle outstanding debts owed to three creditors and one …

Read More

On July 2, 2024 BVT announced that it has entered into debt settlement agreements (the “Settlement Agreements”) to fully settle outstanding debts owed to three creditors and one director (the …

Read More

On June 26, 2024 BVT announced an R&D agreement with Syensqo (2NF.F) (SYENS.BR) to develop its proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) into a seed treatment formulation …

Read More